Tango's vopimetostat+daraxonrasib shows 82% ORR in 2L/3L PDAC; Phase 3 planned, workforce cut 14%

Tango Therapeutics, Inc.

Phase 1/2: 82% ORR (18/22) in 2L/3L MTAP-deleted/RAS-mutant PDAC; median PFS not reached, 88% 9-month PFS, 100% DCR at Aug 20, 2026 cutoff.
Dose level 1 vopimetostat 200 mg + daraxonrasib 100 mg daily well tolerated: no DLTs, no Grade 4/5 TRAEs, Grade 3 TRAEs 40%; dose level 2 had 3 DLTs in 2 patients.
FDA-aligned Phase 3 in front-line MTAP-deleted PDAC to randomize 1:1 vopimetostat+daraxonrasib vs standard chemotherapy, dual primary endpoints ORR and PFS, starting 1H 2027.
Zoldonrasib combo in MTAP-deleted/KRAS G12D PDAC: 54% ORR (19/35), 61% 9-month PFS, 97% DCR; NSCLC daraxonrasib combo 80% ORR (4/5).
Board approved Oct 22 strategic reprioritization: focus on PRMT5/vopimetostat/TNG456, halt certain preclinical work, cut workforce ~14%, mostly research.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.